These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12452746)

  • 21. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient.
    Basic-Jukic N; Kes P; Bubic-Filipi L; Vranjican Z
    Nephrol Dial Transplant; 2010 Jun; 25(6):2036; author reply 2036-7. PubMed ID: 20332417
    [No Abstract]   [Full Text] [Related]  

  • 23. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure.
    Al Shohaib S
    Am J Nephrol; 2000; 20(3):212-3. PubMed ID: 10878403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simvastatin-fluconazole causing rhabdomyolysis.
    Shaukat A; Benekli M; Vladutiu GD; Slack JL; Wetzler M; Baer MR
    Ann Pharmacother; 2003; 37(7-8):1032-5. PubMed ID: 12841814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome.
    Appel-Dingemanse S; Smith T; Merz M
    J Clin Pharmacol; 2002 Mar; 42(3):312-8. PubMed ID: 11865968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluvastatin and cancer.
    Mascitelli L; Pezzetta F
    Int J Clin Pract; 2007 Jan; 61(1):168; author reply 168-9. PubMed ID: 17229191
    [No Abstract]   [Full Text] [Related]  

  • 30. Severe rhabdomyolysis after laparoscopic surgery for adenocarcinoma of the rectum in two patients treated with statins.
    Forestier F; Breton Y; Bonnet E; Janvier G
    Anesthesiology; 2002 Oct; 97(4):1019-21. PubMed ID: 12357176
    [No Abstract]   [Full Text] [Related]  

  • 31. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
    Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P
    Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rhabdomyolysis and acute renal failure secondary to statins].
    Borrego FJ; Liébana A; Borrego J; Pérez del Barrio P; Gil JM; García Cortés MJ; Sánchez Perales C; Serrano P; Pérez Bañasco V
    Nefrologia; 2001; 21(3):309-13. PubMed ID: 11471312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rhabdomyolysis with concurrent atorvastatin and diltiazem.
    Lewin JJ; Nappi JM; Taylor MH
    Ann Pharmacother; 2002 Oct; 36(10):1546-9. PubMed ID: 12243603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
    Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
    Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction.
    Sipe BE; Jones RJ; Bokhart GH
    Ann Pharmacother; 2003 Jun; 37(6):808-11. PubMed ID: 12773066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and lipid-lowering effect of fluvastatin in hypercholesterolaemic patients on maintenance haemodialysis.
    Ichimaru N; Takahara S; Moriyama T; Kondo M; Nonomura N; Tanaka T; Wang JD; Imai E; Okuyama A; Kondo Y
    J Int Med Res; 2004; 32(1):45-52. PubMed ID: 14997705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhabdomyolysis in a patient treated with colchicine and atorvastatin.
    Tufan A; Dede DS; Cavus S; Altintas ND; Iskit AB; Topeli A
    Ann Pharmacother; 2006; 40(7-8):1466-9. PubMed ID: 16772404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
    Lee AJ; Maddix DS
    Ann Pharmacother; 2001 Jan; 35(1):26-31. PubMed ID: 11197581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rhabdomyolysis and HMG-CoA reductase inhibitors.
    Omar MA; Wilson JP; Cox TS
    Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
    Choe EY; Wang HJ; Kwon O; Cho Y; Huh KH; Kim MS; Kim YS; Ahn CW; Cha BS; Lee HC; Kang ES
    Transplantation; 2014 Feb; 97(4):419-25. PubMed ID: 24285338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.